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Abstract Anandamide (ANA) inhibits prolactin- and nerve
growth factor (NGF)-induced proliferation of human breast
cancer cells by decreasing the levels of the 100 kDa prolactin
receptor (PRLr) and the high affinity trk NGF receptor,
respectively, and by acting via CB1-like cannabinoid receptors.
However, the intracellular signals that mediate these effects are
not known. Here, we show that, in MCF-7 cells: (i) forskolin and
the mitogen-activated protein kinase (MAPK) kinase inhibitor
PD098059 prevent, and the protein kinase A inhibitor RpcAMPs
mimics, the inhibitory effects of ANA on cell proliferation and
PRLr/trk expression and (ii) ANA inhibits forskolin-induced
cAMP formation and stimulates Raf-1 translocation and MAPK
activity, in a fashion sensitive to the selective CB1 antagonist
SR141716A. ANA stimulation of MAPK was enhanced by
inhibitors of ANA hydrolysis. Forskolin inhibited MAPK and
ANA-induced Raf-1 translocation. These findings indicate that,
in MCF-7 cells, ANA inhibits adenylyl cyclase and activates
MAPK, thereby exerting a down-regulation on PRLr and trk
levels and a suppression of cell proliferation.
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1. Introduction
The ¢nding of two receptor subtypes for (3)-v9-tetrahydro-
cannabinol (THC), the CB1 and the CB2 receptor, led to the
discovery of two endogenous ligands for such proteins (see [1]
for review): anandamide (N-arachidonoyl-ethanolamine,
ANA) [2] and 2-arachidonoyl glycerol (2-AG) [3,4] (hereafter
referred to as ‘endocannabinoids’ [5]). The pharmacology and
metabolism of these two metabolites have been studied (for
reviews, see [5^7]), but their actual pathophysiological role(s)
in vivo remain(s) to be elucidated. Most of the possible func-
tions suggested so far for endocannabinoids are concerned
with speci¢c activities in particular cell types and tissues [5^
8]. However, THC and endocannabinoids also modulate basic
functions that are common to many cell types, such as energy
metabolism (see [9] for review) and cell structure, proliferation
and apoptosis [10^13]. We reported that ANA and the syn-
thetic cannabinoid HU-210 inhibit the proliferation of human
breast cancer cells (HBCCs) by down-regulating the levels of
the V100 kDa form of the receptor (PRLr) of prolactin, a
hormone that is synthesized by these cells in culture and used
as an autocrine mitogen [12]. We showed that ANA, 2-AG
and HU-210 also potently inhibit the nerve growth factor
(NGF)-induced proliferation of a HBCC line, the MCF-7
cells, by suppressing the levels of the high a⁄nity trk NGF
receptors [14]. We found that the anti-mitogenic e¡ects of
ANA, as well as its down-regulatory action on PRLr/trk pro-
teins, were mediated by CB1-like, and not CB2-like, receptors
[14]. In another study, we showed that THC causes an alto-
gether unrelated e¡ect, i.e. the apoptosis of glioma, astrocy-
toma and neuroblastoma cells, but not of neurons and astro-
cytes in primary culture, by acting through sphingomyelin
hydrolysis in a fashion insensitive to the selective CB1 antag-
onist SR141716A [13]. These studies point to the possible
development of novel anti-cancer drugs from both synthetic
and endogenous cannabinoids. To this end, it is of interest to
identify the intracellular events leading to the down-regulation
of the expression of PRLr and trk that is responsible for CB1-
mediated inhibition of HBCC proliferation. In fact, drugs
capable of selectively interfering with such events may mimic
the anti-cancer e¡ects of cannabinoids without producing
their undesired psychotropic actions. CB1 receptor activation
modulates the activity of adenylyl cyclase (AC) and mitogen-
activated protein kinase (MAPK) (see [15] for review), thereby
potentially regulating the expression of several genes. The
cAMP/protein kinase A (PKA) pathway may also in£uence
gene transcription by modulating the activity of MAPK [16].
trk receptors have been shown to be up-regulated by cAMP
[17,18], but similar data for PRLr have not been reported yet.
Based on this background, the present study was aimed at
investigating the involvement of the cAMP/PKA and Raf-1/
MAPK pathways in the inhibition of HBCC proliferation and
PRLr/trk levels by ANA.
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2. Materials and methods
2.1. Materials
MCF-7 and EFM-19 cells were purchased from ATCC (USA) and
DSM (Germany), respectively, and cultured as advised by the manu-
facturers. ANA, human prolactin, 8-Br-cAMP and L-NGF were pur-
chased from Sigma and forskolin from Fluka. SR141716A was a gift
from Sano¢ Recherche, Montpellier, France, and HU-210 from Dr.
R. Mechoulam, Hebrew University, Jerusalem, Israel. RpcAMPs was
purchased from Biomol, USA, and PD098059 from Alexis Corp.,
USA. The concentrations of test substances (i.e. ANA, SR141716A,
forskolin, RpcAMPs) used in di¡erent assays depended on the assay
conditions, lower concentrations being used in long-incubation experi-
ments (e.g. cell proliferation, assay of trk/PRLr levels).
2.2. Cell proliferation assays and ANA degradation by MCF-7 cells
Cell proliferation assays were carried out according to the method
previously described [12,14] in six-well dishes containing sub-con£uent
cells (at a density of about 50 000 cells/well). With MCF-7 cells, test
substances were introduced 3 h after cell seeding and then daily at
each change of medium. With EFM-19 cells, test substances were
introduced 24 h after cell seeding and then daily at each change of
medium, in the presence or absence of 50 ng/ml of human prolactin.
Cells were counted by a hemocytometer after 4 days from the addition
of test substances. In order to study the e¡ect of NGF on MCF-7 cell
proliferation, we used a previously described procedure [19]. Twenty-
four hours after cell seeding (50 000 cells/well), the medium was
changed to serum-free medium and cells starved for 24 h. Cells
were then treated with serum-free medium containing L-NGF
(100 ng/ml) plus test substances or vehicle and counted after 48 h.
The time-dependent degradation of [14C]ANA (80 000 cpm, 1.5 WM in
8 ml of serum-free culture medium) by intact, sub-con£uent MCF-7
cells was measured as described previously [20].
2.3. E¡ect on trk and PRLr levels
After treatment with test substances, which was carried out under
the same conditions described above for cell proliferation assays, but
in 100 mm Petri dishes, cells were washed twice with 137 mM NaCl,
3 mM KCl, 12 mM Na2HPO4, 2 mM KH2PO4 (pH = 7.4) and then
lysed with a lysis bu¡er consisting of 50 mM Tris-HCl, pH = 7.4,
1 mM EDTA, 150 mM NaCl, 1 mM Na3VO4, 1 mM NaF, 1% Non-
idet P-40, 0.25% sodium deoxycholate, 1 mM phenyl methyl sulfonyl
£uoride (PMSF), 1% Triton X-100 and 1 Wg/ml each of aprotinin,
leupeptin and pepstatin A. Lysates were loaded onto gels containing
10% and 7.5% polyacrylamide for the blotting of PRLr or trk, respec-
tively. Proteins were transferred to nitrocellulose membranes, which
were then incubated ¢rst for 1 h at room temperature with the pri-
mary antibody, i.e. either anti-human prolactin receptor monoclonal
antibody (U5, purchased from A⁄nity Bioreagents, Golden, USA,
1:1000) or anti-mouse trk monoclonal antibody (B-3, Santa Cruz
Biotechnologies, USA, 1:500) and then with the appropriate horse-
radish peroxidase-labelled secondary antibody conjugates (1:5000,
Bio-Rad, Hercules, USA). Bands were visualized by the ECL tech-
nique (Bio-Rad).
2.4. cAMP, MAPK and Raf-1 translocation assays
cAMP assays were performed on intact con£uent MCF-7 cells
plated in six-well dishes and stimulated for 10 min at 37‡C with
1 WM forskolin in 400 Wl of serum-free Dulbecco’s modi¢ed Eagle’s
medium containing 20 mM HEPES, 0.1 mg/ml BSA, 0.1 mM 1-meth-
yl-3-isobutylxanthine (Sigma). Cells were treated with either vehicle
(ethanol) or ANA, at various concentrations, or ANA plus 0.5 WM
SR141716A. After the incubation, cells were extracted and cAMP was
determined by means of a cAMP assay kit (Amersham, UK). p42/p44
MAPK activity was determined in cell extracts as the incorporation of
32P from [32P]ATP into a MAPK substrate peptide [21]. Membrane-
bound Raf-1 was determined by Western blot analysis with an anti-
Raf-1 antibody (Santa Cruz Biotechnology, USA) as described before
[21]. For both assays, cells were incubated with ANA for 30 min at
37‡C. In some experiments, cells were pre-incubated with ANA hy-
drolysis inhibitors for 30 min at 37‡C, followed by co-incubation with
ANA for 30 min. In some experiments, SR141716A was co-incubated
with ANA.
3. Results
3.1. E¡ect of forskolin, RpcAMPs and PD098059 on basal and
NGF-induced HBCC proliferation
ANA inhibits basal MCF-7 and EFM-19 cell proliferation
with IC50 = 1.4 þ 0.9 and 1.5 þ 0.3 WM (n = 6 and 7, respec-
tively; see [12,14]). As shown in Fig. 1A, forskolin weakly
inhibited MCF-7 cell proliferation (311 þ 1% inhibition at
10 WM) but signi¢cantly reduced ANA anti-proliferative e¡ect
on these cells. Forskolin also blocked the inhibition by ANA
of both basal and prolactin-induced proliferation of EFM-19
cells (data not shown), which were even less sensitive than
MCF-7 cells to forskolin alone (maximal inhibition of prolif-
eration was 36 þ 1% at 10 WM). Forskolin inhibited ANA
anti-proliferative action on L-NGF-induced MCF-7 cell pro-
liferation (estimated IC50 = 1.2 WM) and weakly inhibited
Fig. 1. Involvement of the cAMP/PKA and MAPK pathways in ANA anti-proliferative e¡ects on MCF-7 cells. E¡ect of forskolin (FSK),
RpcAMPs and PD098059 (at various concentrations) on (A) basal and (B) L-NGF-induced MCF-7 cell proliferation, as well as on the inhibi-
tion by ANA of (A) basal and (B) L-NGF-induced MCF-7 cell proliferation. Data are means þ S.D. of at least three separate experiments car-
ried out in duplicate. *, P6 0.05 vs. ANA only, as assessed by ANOVA.
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L-NGF-induced MCF-7 cell proliferation (325 þ 1% inhibi-
tion at 10 WM) (Fig. 1B). The PKA inhibitor RpcAMPs
dose-dependently inhibited both basal and L-NGF-induced
MCF-7 cell proliferation. The e¡ect of a submaximal dose
of this compound was not cumulative to that of a submaximal
dose of ANA (Fig. 1A,B). This ¢nding was con¢rmed in
EFM-19 cells, where di¡erent concentrations of RpcAMPs
were tested. The cytostatic e¡ect of 2.5 WM ANA alone
(353 þ 2%) was not increased by 5 WM RpcAMPs (which
alone produced 311 þ 2% inhibition), 10 WM RpcAMPs
(which alone produced 320 þ 5% inhibition) or 25 WM
RpcAMPs (which alone produced 355 þ 5% inhibition), since
the cumulative e¡ects in the three cases were 346 þ 4, 343 þ 4
and 363 þ 7%, respectively (means þ S.D., n = 3). We also
tested two di¡erent doses (25 and 100 WM) of 8-Br-cAMP
on cell proliferation. Unfortunately, this compound was toxic
to HBCCs after long-term (s 2 days) treatments and could
not be used in experiments aimed at determining possible
cytostatic e¡ects. Finally, the MAPK kinase inhibitor
PD098059 dose-dependently inhibited basal but not L-NGF-
induced MCF-7 cell proliferation and, at a weakly active dose
(1 WM), suppressed both ANA and HU-210 inhibition of
MCF-7 cell proliferation (Fig. 1A,B). Interestingly, MCF-7
cells rapidly inactivate exogenous [14C]ANA. After 10 min,
more than half of the [14C]ANA incubated with cells had al-
ready been cleared from the medium (t1=2 = 7 þ 1 min). Hy-
drolysis to [14C]ethanolamine proceeded more slowly
(t1=2 = 20 þ 3 min), as previously shown for neurons [22].
3.2. E¡ect of forskolin, RpcAMPs and PD098059 on MCF-7
cell trk and PRLr levels
As assessed by Western immunoblotting using the appro-
priate antibodies, MCF-7 cells express both PRLr and the
V140 kDa trk high a⁄nity receptors for NGF (Fig. 2A,B).
As reported previously [12,14], incubation of cells with ANA
led to suppression of both PRLr and trk levels. Both forskolin
and PD098059, at concentrations exerting only slight anti-
proliferative e¡ects but a maximal prevention of ANA anti-
mitogenic e¡ects, antagonized the down-regulatory e¡ect of
ANA on PRLr and trk levels. PD098059 also attenuated the
HU-210 e¡ect on trk levels. RpcAMPs, at concentrations ef-
fecting strong inhibition of cell proliferation, decreased both
PRLr and trk levels (Fig. 2A,B).
3.3. E¡ect of ANA on cAMP levels, MAPK and Raf-1
translocation in HBCCs
ANA dose-dependently inhibited forskolin-induced cAMP
formation in MCF-7 cells (Fig. 3A). The e¡ect was half-max-
imal with 3.5 WM ANA and was blocked by 0.5 WM
SR141716A. Analogous results were obtained for EFM-19
cells (data not shown). Little inhibition by ANA (80 þ 1% of
control, n = 3) of basal cAMP levels was observed in both
HBCC lines. As shown in Fig. 3B, ANA induced a dose-
dependent activation of MAPK activity. The stimulatory ef-
fect of ANA was half-maximal at around 10 WM and was
antagonized by 5 WM SR141716A (Table 1). Forskolin and
8-Br-cAMP inhibited basal MAPK activity but did not pre-
vent ANA activation of MAPK (Fig. 3, Table 1). However,
MAPK activity in the presence of ANA and either forskolin
or 8-Br-cAMP was signi¢cantly lower than that in the pres-
ence of ANA alone (Fig. 3, Table 1). By contrast, RpcAMPs
stimulated MAPK. ANA-induced MAPK activation was po-
tentiated by the ANA amidohydrolase irreversible inhibitor
PMSF and by oleamide (Table 1), which is a substrate of
the enzyme and a competitive inhibitor of ANA hydrolysis
(for review, see [23]). PMSF and, particularly, oleamide per
se also stimulated MAPK. Finally, ANA increased the
amounts of membrane-bound Raf-1 at a concentration lead-
ing to full MAPK activation. This e¡ect was prevented by
forskolin (Fig. 3C).
Fig. 2. Involvement of the cAMP/PKA and MAPK pathways in the
down-regulatory e¡ect of ANA on the levels of (A) the high molec-
ular weight (V100 kDa) prolactin receptor (PRLr) and (B) the high
a⁄nity trk NGF receptors in MCF-7 cells. PRLr and trk were iden-
ti¢ed by Western immunoblotting by using the appropriate antibod-
ies. The mobility of molecular weight markers is shown. In (A), the
e¡ect of RpcAMPs (50 WM) on PRLr levels and of forskolin (FSK,
10 WM) and PD098059 (PD, 1 WM) on ANA (1 WM) suppression of
PRLr levels is shown. The same amount of protein (50 Wg) was
loaded onto each lane. In (B), the e¡ect on PRLr and trk levels of
forskolin (FSK, 10 WM) and PD098059 (PD, 1 WM) alone or in the
presence of ANA (1 WM), or of RpcAMPs (Rp, 25 and 50 WM) is
shown. Also the e¡ect of HU-210 (2.5 WM) with or without
PD098059 (PD, 1 WM) is shown. The anti-trk antibody cross-reacts
with human trk. The same amount of protein (20 Wg) was loaded
onto each lane. Representative of three experiments yielding similar
results. Cont, control.
Table 1
E¡ect of modulators of AC, PKA and ANA hydrolysis on ANA
stimulation of MAPK in MCF-7 cells
Additions MAPK activity (%)
None 100 þ 13
10 WM ANA 142 þ 9*
25 WM ANA 201 þ 29*
25 WM forskolin 64 þ 15*
25 WM ANA+25 WM forskolin 155 þ 16*#
50 WM 8-Br-cAMP 76 þ 8*
25 WM ANA+50 WM 8-Br-cAMP 158 þ 8*#
25 WM RpcAMPs 148 þ 19*
5 WM SR141716A 101 þ 3
25 WM ANA+5 WM SR141716A 100 þ 4#
50 WM oleamide 176 þ 24*
10 WM ANA+50 WM oleamide 301 þ 44*#
1 mM PMSF 138 þ 6*
10 WM ANA+1 mM PMSF 205 þ 31*#
Cells were exposed to the di¡erent agents for 30 min. In the case of
incubations with PMSF and oleamide, cells were pre-incubated with
these compounds for 30 min before ANA was added. Data are
means þ S.D. of four separate experiments. *, P6 0.01 vs. control
incubations as assessed by the paired Student’s t test. #, P6 0.01
vs. ANA only. The e¡ect of oleamide on MAPK activity is in
agreement with our previous observation that this compound per se
also inhibits HBCC proliferation by enhancing endocannabinoid lev-
els [20].
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4. Discussion
It is known that HBCCs synthesize prolactin and use it as
an autocrine growth factor [12,24]. We showed that ANA, by
acting at CB1-like receptors, can inhibit both basal (i.e. en-
dogenous prolactin-induced) and exogenous prolactin or L-
NGF-induced HBCC proliferation by suppressing the levels
of PRLr and the high a⁄nity trk NGF receptors, respectively
[12,14]. Here, we studied the molecular mechanisms by which
ANA exerts these e¡ects. We found that ANA stimulated
MAPK and inhibited AC in a fashion sensitive to
SR141716A. Drugs interfering with either the cAMP/PKA
or the MAPK pathways a¡ected in a similar manner both
the inhibition of cell proliferation and the suppression of
PRLr/trk levels by ANA. In particular, we observed that the
AC activator, forskolin, and the MAPK kinase inhibitor,
PD098059, counteracted, whereas the PKA inhibitor,
RpcAMPs, mimicked these two e¡ects of the endocannabi-
Fig. 3. E¡ect of ANA on intracellular signals in MCF-7 cells. (A) E¡ect on forskolin-induced cAMP formation. Data are means þ S.D. of three
separate experiments. Control levels of cAMP after 10 min stimulation of cells with 1 WM forskolin were 63.2 þ 5.5 pmol/well, whereas basal
cAMP levels were 8.4 þ 1.5 pmol/well (n = 6). *, P6 0.05 vs. ANA plus SR141716A, as assessed by ANOVA. (B) E¡ect of ANA on MAPK ac-
tivity in MCF-7 cells. Cells were exposed for 30 min to di¡erent concentrations of ANA in the absence (open circles) or presence (¢lled circles)
of 25 WM forskolin. Data are means þ S.D. of four separate experiments. (C) E¡ect of ANA on Raf-1 translocation to the membrane fraction
in MCF-7 cells. Cells were incubated for 30 min in the absence or presence of ANA (25 WM) and/or forskolin (FSK, 25 WM). Upper panel:
representative luminogram. Lower panel: relative values of membrane-bound Raf-1 protein. Data are means þ S.D. of six separate experiments.
*, P6 0.01 vs. control incubations as assessed by the paired Student’s t test.
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noid, thus suggesting the involvement of the cAMP/PKA and
MAPK signalling cascades in ANA inhibition of PRLr/trk
levels and cell proliferation.
We found that RpcAMPs stimulated, whereas forskolin in-
hibited, basal MAPK activity. However, forskolin alone did
not inhibit Raf-1 translocation to the cell membrane. This
suggests that, in MCF-7 cells, MAPK is constitutively
down-regulated only in part through the PKA-catalyzed phos-
phorylation, and subsequent inhibition, of Raf-1 [16]. CB1-
mediated inhibition of AC by ANA may release this inhibi-
tory tone and potentially restores MAPK activity by enhanc-
ing Raf-1 translocation, an e¡ect that is reversed by forskolin.
It is likely that ANA activates MAPK also independently
from its e¡ect on AC (as shown for synthetic cannabinoids
in astrocytoma cells [25]) and Raf-1 translocation, thus ex-
plaining why forskolin did not prevent ANA-induced
MAPK stimulation. However, only the putative cAMP-de-
pendent activation of MAPK by ANA would lead to inhib-
ition of cell proliferation. In fact, if also the ‘direct’ e¡ect of
ANA on MAPK resulted in the inhibition of cell prolifera-
tion, there should have been a cumulative cytostatic action
with submaximal doses of RpcAMPs (which mimics only
the cAMP-dependent e¡ect on the enzyme) and ANA, which
we did not observe (Fig. 1 and Section 3). This latter ¢nding
may also indicate that, additionally, ANA reduces the prolif-
eration of MCF-7 cells by inhibiting cAMP formation without
passing through MAPK activation. Indeed, inhibition of
cAMP formation by peptide YY was recently shown to lead
to inhibition of MCF-7 cell growth in vitro and in vivo [26].
The indirect stimulation of MAPK by ANA is also strongly
supported by (1) a recent study in which over-expression of
mutant-activated GKs subunits or incubation with 8-Br-
cAMP were found to decrease the intrinsic activity of ERK-
1 and ERK-2 kinases in MCF-7 cells [27] and (2) our present
observation that ANA a¡ects cAMP levels at doses slightly
lower than those required to stimulate MAPK. The fact that
the IC50 and EC50 values for these two e¡ects are in the low
WM range of concentrations should not lead to the conclusion
that ANA action on the two systems is non-physiological or is
not mediated by cannabinoid receptors. In fact, both e¡ects
were blocked by SR141716A and the relative IC50 and EC50
values were only 3^6-fold higher than the Ki values for ANA
displacement of [3H]SR141716A from HBCC membranes
(0.85^1.50 WM) or the IC50 values for ANA inhibition of
HBCC proliferation (1.4^1.5 WM, see [12,14]). Furthermore,
ANA e¡ect on cAMP levels and MAPK activity was very
probably blunted by the occurrence of enzymatic hydrolysis
during the assays. Indeed, we have shown here and previously
[12,20] that HBCCs rapidly hydrolyze [14C]ANA. Accord-
ingly, inhibitors of the enzymatic hydrolysis of ANA (e.g.
PMSF and oleamide) signi¢cantly enhanced its e¡ect both
on cell proliferation and MAPK activity (this study and
[12]). Interestingly, PMSF and, particularly, oleamide per se
also induced MAPK activation. These e¡ects may be due to
the enhancement of endogenous ANA levels and are in agree-
ment with our previous ¢nding that oleamide per se also in-
hibits HBCC proliferation (in fact, the anti-proliferative e¡ect
of oleamide, which does not bind to CB1 receptors, was
blocked by SR141716A [20]). Nevertheless, oleamide may
also exert part of its e¡ects independently from ANA hydrol-
ysis [28].
An additional factor that might have led to observe rela-
tively high IC50 and EC50 values for ANA inhibition of cAMP
formation and stimulation of MAPK is that short incubation
times are normally used in the assay protocols for these two
e¡ects. It is possible that longer incubations (such as those
used to observe the anti-mitogenic and anti-PRLr/trk e¡ects
of the lipid) might have led to an action on cAMP levels or,
particularly, MAPK activity with lower ANA concentrations
and, subsequently, to a counteraction of these e¡ects with
doses of forskolin and SR141716A closer to those required
to antagonize ANA inhibition of cell proliferation. Also a
more potent inhibition of the basal cAMP formation by
ANA might have been observed with longer incubations. It
is possible that only after prolonged treatment, low doses of
ANA lead to e¡ects on basal cAMP levels or MAPK activity
strong enough to inhibit PRLr/trk levels and MCF-7 cell pro-
liferation. This hypothesis agrees with previous observations
that sustained, as opposed to transient, activation of MAPK
is necessary to observe inhibition, instead of activation, of
MCF-7 cell proliferation [29]. In fact, both activation and
inhibition of MAPK have been previously shown to lead to
inhibition of HBCC growth, depending on the culturing con-
ditions and on the presence and concentration of growth fac-
tors. For example, incubation of MCF-7 cells with basic ¢-
broblast growth factor at concentrations that e¡ected growth
inhibition resulted in activation of both ERK-1 and ERK-2
[30]. On the other hand, inhibition of MAPK activity by tu-
mor necrosis factor-K was described to lead to growth inhib-
ition in epidermal growth factor-stimulated cells [31]. Thus,
our ¢nding of the inhibitory e¡ect on basal MCF-7 cell pro-
liferation by PD098059 and of the counteraction by the latter
compound of ANA anti-proliferative e¡ects both agree with
previous data. It is possible that a ¢nely regulated tone of
MAPK activity is necessary to these cells for normal prolifer-
ation. Disruption of this tone by either blockade (with
PD098059) or sustained dis-inhibition (by CB1-mediated in-
hibition of cAMP levels) may lead to decreased proliferation.
In conclusion, we have shown here that the suppression of
PRLr and trk levels by ANA and its inhibition of prolactin
and NGF-induced MCF-7 cell proliferation may be due, at
least in part, to AC inhibition and MAPK activation. Our
data are in agreement with reports indicating that the tran-
scription of trk genes is enhanced by the cAMP/PKA cascade
[17,18]. However, to the best of our knowledge, ours is the
¢rst report of the suppression of both PRLr and trk levels
following inhibition of the cAMP/PKA pathway and stimula-
tion of MAPK.
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